Tempest Therapeutics
TPST
33 hedge funds and large institutions have $6.68M invested in Tempest Therapeutics in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 10 closing their positions.
6.93% less ownership
Funds ownership: 27.53% → 20.6% (-6.9%)
20% less funds holding
Funds holding: 41 → 33 (-8)
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
80% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 10
82% less capital inflows, than outflows
Capital inflows: $458K | Capital outflows: $2.53M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$364K |
| 2 |
Panagora Asset Management
Boston,
Massachusetts
|
+$31.6K |
| 3 |
Two Sigma Investments
New York
|
+$31.6K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$13.2K |
| 5 |
Morgan Stanley
New York
|
+$2.64K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$458K |
| 2 |
Broadfin Capital
New York
|
-$442K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$387K |
| 4 |
TS
Third Security
Radford,
Virginia
|
-$303K |
| 5 |
Franklin Resources
San Mateo,
California
|
-$290K |
TPST Hedge Fund Activity: Q2 2018 in Review
33 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q2 2018, worth a combined $6.68M — down 16% from $7.97M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of TPST and 2 opened new positions — a net loss of 8 holders — while 9 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $364K. The largest seller was Sabby Management, cutting an estimated $458K.
- 33 institutional investors held Tempest Therapeutics (TPST) as of Q2 2018, down from 41 in Q1 2018.
- Funds reported $6.68M of Tempest Therapeutics stock for Q2 2018, down 16% quarter-over-quarter.
- 2 funds opened new Tempest Therapeutics positions in Q2 2018 and 10 closed out, a net change of -8 holders.
- The largest Tempest Therapeutics buyer in Q2 2018 was Renaissance Technologies, an estimated $364K added.
- The largest Tempest Therapeutics seller in Q2 2018 was Sabby Management, an estimated $458K sold.
Based on aggregated 13F filings for Q2 2018.